PT Phapros, Tbk

Jakarta Stock Exchange PEHA.JK

PT Phapros, Tbk Total Non-Current Liabilities for the year ending December 31, 2023: USD 17.36 M

PT Phapros, Tbk Total Non-Current Liabilities is USD 17.36 M for the year ending December 31, 2023, a -16.35% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

PT Phapros, Tbk Total Non-Current Liabilities for the year ending December 31, 2022 was USD 20.75 M, a -18.91% change year over year.
PT Phapros, Tbk Total Non-Current Liabilities for the year ending December 31, 2021 was USD 25.59 M, a 178.99% change year over year.
PT Phapros, Tbk Total Non-Current Liabilities for the year ending December 31, 2020 was USD 9.17 M, a 39.43% change year over year.
PT Phapros, Tbk Total Non-Current Liabilities for the year ending December 31, 2019 was USD 6.58 M, a -11.35% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Jakarta Stock Exchange: PEHA.JK

PT Phapros, Tbk

CEO	Ms. Ida Rahmi Kurniasih
IPO Date	Dec. 26, 2018
Location	Indonesia
Headquarters	Rajawali Tower 17th Floor
Employees	1,384
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

PT Phapros, Tbk operates in the pharmaceutical and health care industry in Indonesia. The company operates through Over the Counter (OTC), Ethical, Generic Drugs Bearing, and Toll Manufacturing segments. It offers OTC drugs, including Antimo Anak, Livron B Plek, Noza, Hemorogard, Bioron, and others. The company also provides generic drug products for government institutions and hospitals, as well as produces drugs for other pharmaceutical industries; and offers medical devices. PT Phapros, Tbk also exports its products internationally. The company was founded in 1954 and is headquartered in Jakarta, Indonesia. PT Phapros, Tbk operates as a subsidiary of PT Kimia Farma (Persero) Tbk.

Key trends

Past 5 years